Phase II open-label study of sunitinib malate (SU011248) in adult patients with metastatic and/or surgically unresectable soft tissue sarcoma.
Phase of Trial: Phase II
Latest Information Update: 27 Aug 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Sarcoma
- Focus Therapeutic Use
- 04 Jan 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
- 04 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Dec 2011 Planned end date changed from 1 Nov 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.